Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: Administration prior to radical prostatectomy

Journal of the Society for Integrative Oncology

Volumn 8, Issue 1, 2010, Pages 3-13

  Kumar, Nagi B ^a   Kang, Loveleen ^b   Pow Sang, Julio ^b   Xu, Ping ^b   Allen, Kathy ^a   Riccardi, Diane ^a   Besterman Dahan, Karen ^a   Krischer, Jeffrey P ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Isoflavones; Ki 67; Prostate cancer; Prostate specific antigen; Steroid hormones

Indexed keywords

AGLYCONE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DAIDZEIN; ESTRADIOL; GENISTEIN; GLYCETIN; ISOFLAVONE; KI 67 ANTIGEN; MULTIVITAMIN; PREVASTEIN HC; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; STEROID HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG; ISOFLAVONE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; MALE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; STEROID BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; BLOOD; PROSTATIC NEOPLASMS;

HUMANS; ISOFLAVONES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN;

EID: 77249154595     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2009.0024     Document Type: Article

References (42)

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2009.
2. Holmberg L, Bill-Axelson A, Garmo H, et al. SPCG-4 Study Group. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 2006;20:845-55.
3. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-19.
4. Kelloff GJ, Leiberman R, Steele VE, et al. Chemoprevention of prostate cancer. Eur Urol 1999;35:342-50.
5. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol Rev 2006;7:355-62.
6. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004;59:141-7.
7. Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991;54:1093-100.
8. Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
9. Morton MS, Chan PS, Cheng C, et al. Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997;32:122-8.
10. Ouchi H, Ishiguro H, Ikeda N, et al. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005; 12:73-80.
11. Adlercreutz H, Mousavi Y, Clark J, et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol 1992;41:331-7.
12. Huang X, Chen S, Xu L, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470-8.
13. Kazi A, Daniel KG, Smith DM, et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003;66:965-76.
14. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004;48:160-70.
15. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126-36.
16. Kumar NB, Krischer JP, Allen K, et al. A phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with prostate cancer. Int J Nutr Cancer 2007;59:163-8.
17. Kumar NB, Krischer JP, Allen K, et al. Safety of purified isoflavones in men with early stage prostate cancer. Int J Nutr Cancer 2007;59:169-75.
18. Freedland SJ, Mangold LA, Walsh PC, Partin AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 2005; 174 (4 Pt 1):1276-81; discussion 1281.
19. Dalais FS, Meliala A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostatespecific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004;64:510-15.
20. deVere White RW, Hackman RM, Soares SE, et al. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 2004;63:259-63.
21. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, et al. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-12.
22. Urban D, Irwin W, Kirk M, et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 2001;165:294-300.
23. Lampe JW, Gustafson DR, Hutchins AM, et al. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 1999;8:699-707.
24. Bhakta D, dos Santos Silva I, Higgins C, et al. A semiquantitative food frequency questionnaire is a valid indicator of the usual intake of phytoestrogens by south Asian women in the UK relative to multiple 24-h dietary recalls and multiple plasma samples. J Nutr 2005;135:116-23.
25. Seow A, Shi CY, Chung FL, et al. Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer Epidemiol Biomarkers Prev 1998;7:135-40.
26. Chen Z, Zheng W, Causter LJ, et al. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shangai. Nutr Cancer 1999;33:82-7.
27. Maskarinec G, Singh S, Meng L, et al. Dietary soy intake and urinary isoflavone excretion among women from a multiethnic population. Cancer Epidemiol Biomarkers Prev 1998;7:613-19.
28. King RA, Broadbent JL, Head RJ. Absorption and excretion of the soy isoflavone genistein in rats. J Nutr 1996;126:176-82.
29. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995; 125(3 Suppl): 777S-83S.
30. Adlercreutz H, Mazur W, Bartels P, et al. Phytoestrogens and prostate disease. J Nutr 2000;130(3):658S-9S.
31. Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;9:2257-60.
32. Carruba G. Estrogens and mechanisms of prostate cancer progression. Ann N Y Acad Sci 2006;1089:201-17.
33. Pomerantz M, Manola J, Taplin ME, et al. Phase I dosefinding study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol 2007;177:2146-50.
34. Daskivich TJ, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol 2006;3:173-8.
35. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98:529-34.
36. Papaconstantinou C, Krischer JP. An automated patient registration and treatment randomized system. J Med Syst 1995;19:445-56.
37. Mucci NR, Rubin MA, Strawderman MS, et al. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 2000;92:1941-2.
38. Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; (4): CD006019.
39. Kranse R, Dagnelie PC, van Kemenade MC, et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebocontrolled study. Int J Cancer 2005;113:835-40.
40. Hussain M, Banerjee M, Sarkar FH, et al. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003;47:111-17.
41. Dalais FS, Melialla A, Wattanapenpaiboon N, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004;64:510-15.
42. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001; 131 (4 Suppl):1362S-75S.